Poland· PL-100545037
Aujemflu
A influenza, inaktiviert, spalt/split virus oder oberflächen-antigen product containing szczepionka przeciw grypie (antygen powierzchniowy), inaktywowana, registered in Poland by Seqirus Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen is registered in 11 of 19 countries.
Countries holding a registration under ATC J07BB02 (influenza, inaktiviert, spalt/split virus oder oberflächen-antigen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen · ATC J07BB02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Szczepionka przeciw grypie (antygen powierzchniowy), inaktywowana
- Manufacturer
- Seqirus Netherlands B.V.
- Country
- Poland (PL)
- ATC code
- J07BB02
- ATC class
- Influenza, inaktiviert, Spalt/Split Virus oder Oberflächen-Antigen
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07BB02
Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen, as other registers publish it.
- PolandAdjupanrixGlaxoSmithKline Biologicals S.A.
- DenmarkAdjupanrixGlaxoSmithKline Biologicals S.A.
- BelgiumAdjupanrixGlaxoSmithKline Biologicals
- IcelandAdjupanrixGlaxoSmithKline Biologicals S.A.*
- FinlandAdjupanrixGlaxoSmithKline Biologicals SA
- CzechiaADJUPANRIXGlaxoSmithKline Biologicals S.A., Rixensart
- IrelandAdjupanrix suspension and emulsion for emulsion for injection. Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)GlaxoSmithKline Biologicals S.A.
- NetherlandsAdjupanrix, (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals, suspensie en emulsie voor emulsie voor injectieGlaxoSmithKline Biologicals S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cb924d99-5122-4d6f-aae1-16424260e926 GET /v1/drugs/cb924d99-5122-4d6f-aae1-16424260e926?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Zawiesina do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "1 dawka (1 ml)",
"packaging": "Rp ¦ EU/1/26/2050/001 ¦ 168462\n1 amp.-strzyk. 1 ml z igłą\nRp ¦ EU/1/26/2050/002 ¦ 168463\n10 amp.-strzyk. 1 ml z igłą\nRp ¦ EU/1/26/2050/003 ¦ 168464\n1 amp.-strzyk. 1 ml bez igły\nRp ¦ EU/1/26/2050/004 ¦ 168465\n10 amp.-strzyk. 1 ml bez igły",
"substance": "Vaccinum influenzae inactivatum ex corticis antigeniis praeparatum A/Wisconsin/67/2022 (H1N1)pdm09-podobny szczep (A/Georgia/12/2022, CVR-167); A/District of Columbia/27/2023 (H3N2)-podobny szczep (A/Victoria/800/2024, CVR-289); B/Austria/1359417/2021-podobny szczep (B/Singapore/WUH4618/2021, typu dzikiego)",
"common_name": "Szczepionka przeciw grypie (antygen powierzchniowy), inaktywowana",
"pl_product_id": "100545037",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about influenza, inaktiviert, spalt/split virus oder oberflächen-antigen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.